FDA regulatory consulting is outside expertise that helps you work out which FDA pathway your product falls under, what evidence and paperwork it needs, and how to stay compliant after launch. A good FDA regulatory consultant is a technical specialist, not a lawyer. You bring one in early, usually once you have a working prototype or preclinical data, and you pick one based on experience with your exact product type. Pathway assessments typically run $20,000 to $100,000 according to NIH guidance.
This guide is for university technology transfer offices, researchers, founders and companies that hold a promising technology and need to know where FDA fits in the road to market.
TL;DR
- An FDA regulatory consultant helps you choose a pathway, prepare documentation and submissions, plan meetings with the agency, and maintain compliance after approval.
- Consultants offer technical and compliance help. Enforcement defense, import detention and criminal exposure call for a regulatory attorney.
- Start after preclinical studies or initial design work at the latest. Starting earlier helps you avoid wasted spending.
- NIH guidance puts regulatory pathway assessments at roughly $20,000 to $100,000, depending on product type, complexity and stage.
- Choose for product-specific experience, a track record, and invoices that itemize hours.
Table of Contents
- What an FDA regulatory consultant actually does
- Consultant or regulatory attorney?
- What services cover product development through post-market
- When to bring in a consultant
- How regulatory work supports commercialization and licensing
- What FDA regulatory consulting costs
- How to choose an FDA regulatory consultant
- Where a commercialization advisor fits
- Common mistakes to avoid
- Working with us
- FAQ
- Sources
What an FDA regulatory consultant actually does
The FDA regulates drugs, biologics, medical devices, diagnostics and combinations of these. Each category has its own pathway, its own evidence standards and its own paperwork. A consultant translates that into a plan for your specific product.
In practice, the work falls into a few buckets:
- Strategy. Which center and pathway apply, what the likely classification is, what data you need and in what order.
- Documentation. Drafting and reviewing submission materials, technical files, protocols and procedures.
- Agency interaction. Preparing questions and briefing packages for meetings with FDA. FDA's meeting procedures describe regulatory meetings with sponsors held at defined stages of product development, where sponsors can seek the agency's advice on development issues.
- Quality and compliance. Building the quality system, readying the team for inspections, and handling post-market obligations.
Consultants often come from scientific or technical backgrounds, and their focus is compliance, documentation and technical writing rather than legal advice. That distinction matters when you decide who to call, which the next section covers.
Consultant or regulatory attorney?
They solve different problems, and many programs eventually need both.
Call a consultant when the question is "what does FDA expect from us, and how do we prepare it?" Examples: choosing between pathways, designing a study that will satisfy reviewers, writing a submission, setting up complaint handling.
Call an attorney when the question is legal: a warning letter, an enforcement action, an import detention, or any situation with potential criminal exposure. An attorney can also offer attorney-client privilege, which a consultant generally cannot.
For a technology that started in a university lab, the early questions are almost always the first kind. The legal questions that do come up early are about patents, ownership and licensing, which are a different specialty from FDA law. We return to that below.
What services cover product development through post-market
FDA oversight does not end at approval or clearance. A consultant's scope can stretch across the whole lifecycle.
Before you file
Early services include regulatory feasibility, pathway assessment, gap analysis against requirements, and planning your first FDA conversations. For devices, FDA's feedback process is built around specific questions you bring to the agency, so the quality of those questions shapes the quality of the feedback. A consultant helps you frame them.
Pathway differences are real. Combination products, which merge drugs, devices and biologics, often require coordination between FDA centers through the Office of Combination Products. The office works with industry to clarify the regulatory path for these products. If your technology straddles categories, this is where experienced guidance saves the most time.
At submission
This is where documentation quality counts. Consultants assemble the technical content, check it against what reviewers will look for, and manage the back-and-forth when FDA has questions.
After launch
Post-market work is easy to underestimate. FDA's inspectional materials for devices cover quality systems, medical device reports, recalls, corrections and removals, complaints, and registration and listing. On the drug side, FDA's postapproval guidance for generic applications says holders must have written procedures for adverse-event surveillance and reporting, submit periodic reports, and keep labeling accurate and current. A consultant can build and audit these systems so they exist before the first inspection.
When to bring in a consultant
Sooner than most teams expect, but not on day one of an idea.
NIH's guidance for life science innovators says to engage consultants early in the research stage for foundational planning and feasibility, and ideally after preclinical studies or initial design stages for pathway assessment. Early involvement helps define regulatory feasibility and avoids wasteful expenditures.
A practical rule: when your team is confident the technology could work, start asking regulatory questions. The startup accelerator Y Combinator notes that digital health companies can start the FDA process sooner than therapeutic companies, because pivoting takes less time and energy.
Signals that it is time:
- You are about to design the study or prototype that will generate your pivotal evidence.
- An investor or licensee asks what your regulatory path and timeline look like.
- You are choosing between a device and a drug or biologic claim for the same technology.
- A university is deciding whether to license a technology and wants to know what the downstream regulatory burden looks like.
How regulatory work supports commercialization and licensing
Regulatory strategy is a commercial asset. A licensee or investor discounts a technology when the path to market is a blank. They pay more for one with a defined pathway, a credible timeline and a budget.
Universities are catching on. Oregon Health & Science University's Regulatory Consultation and Assistance Program, for example, aims to streamline commercialization through early regulatory review. Consultants in that model assess commercialization pathways, support device or study design, advise on product or protocol development, and plan FDA engagement.
For a tech transfer office, that translates into practical benefits:
- Marketing summaries that state the likely regulatory path.
- Better-informed licensing terms, such as diligence milestones that match how long regulatory steps really take.
- Cleaner conversations with startups spinning out of the lab.
What FDA regulatory consulting costs
Prices vary because projects do. NIH's guidance says costs depend on product type, project complexity and development stage, and that regulatory pathway assessments generally cost between $20,000 and $100,000. A full submission program or quality system build is a larger commitment than a pathway assessment.
What moves the number:
| Factor | Why it changes scope |
|---|---|
| Product type | A software tool, a diagnostic and a novel biologic need very different evidence |
| Complexity | Combination products and first-of-a-kind technologies take more analysis |
| Development stage | Early feasibility work is lighter than a full submission build |
| Engagement model | A defined deliverable differs from open-ended advisory support |
The same NIH guidance describes a comprehensive approach in which invoices report the hours behind each charge, which supports accountability and later auditing. Ask for that up front.
How to choose an FDA regulatory consultant
NIH's guidance gives a simple checklist. Assess candidates on industry-specific experience, understanding of the relevant agencies, a track record of successful projects, and transparent billing. Put the most weight on proven expertise in your product type, whether drug, device or diagnostic.
For early-stage companies, Y Combinator advises looking for consultants who know both your therapeutic or diagnostic domain and the pathway you are considering.
Questions worth asking in the first call:
- Which products like mine have you taken through this pathway, and what was your role?
- Who will do the work, and who will only appear in the pitch?
- What is the deliverable, and what does a finished pathway assessment look like?
- How do you bill, and will invoices show hours?
- Do you have non-conflict agreements that limit who you can work with?
The last question deserves attention. NIH notes that the consultants most familiar with your product type may be the best match, but non-conflict agreements with their current clients can limit availability. Better to learn that before you share confidential data.
Where a commercialization advisor fits
Regulatory strategy rarely stands alone. It interacts with IP strategy (what you can protect and when you disclose), licensing terms (who carries regulatory cost and risk), funding (which grants fit your stage) and company formation (what entity holds the technology). Teams that treat these as separate projects tend to find the conflicts late.
We see the same pattern again and again. A research team has a promising device or therapeutic, and the first question they ask is about a patent or a license. The regulatory question comes later, often after a term sheet has already fixed assumptions about timeline and cost.
Our team has worked inside major university technology transfer offices, in startup leadership, in federal grant review and in industry commercialization. That mix is why we treat regulatory planning as part of commercialization rather than a separate chore. When we assess a life sciences or medical device technology, we look at the patent position, the likely licensing structure, the funding options, including SBIR/STTR and other non-dilutive grants, and the path to market together.
We work with a dedicated IP law partner for legal matters, so patent and licensing work stays integrated. For FDA-specific submissions and technical regulatory writing, we help you scope what you need and make introductions, so the right specialist is working from a commercial plan that already makes sense.
the author
Common mistakes to avoid
- Waiting for a finished product. Design choices made before regulatory input can force repeat testing later.
- Hiring on price alone. A cheap assessment from someone who has never handled your product type can cost more in redone work.
- Treating a consultant as counsel. Keep legal questions with an attorney.
- Skipping post-market planning. Complaint handling, reporting and labeling obligations start when you launch, so budget for them before you need them.
- Leaving the licensee out. If a university is licensing the technology, agree on who owns regulatory work and who pays for it in the license.
Working with us
If you hold a life sciences, biopharma or medical device technology and need to connect regulatory thinking with IP, licensing, funding and company formation, that is the work we do. Our services include IP and patent strategy, licensing support, spinout formation, life sciences and medical device commercialization, go-to-market planning, investor introductions, and funding strategy.
See our consulting services for the full list, or start from the Tech Transfer Advisors home page to tell us about your technology.
FAQ
What does an FDA regulatory consultant do?
An FDA regulatory consultant helps you understand and meet FDA requirements for your product. That includes choosing a pathway, preparing documentation and submissions, planning agency meetings, and maintaining compliance after launch. Most have scientific or technical backgrounds and focus on compliance rather than legal advice.
How much does FDA regulatory consulting cost?
Costs depend on product type, complexity and development stage. NIH guidance says regulatory pathway assessments generally cost between $20,000 and $100,000. Larger programs, such as full submission preparation, are scoped separately, so ask for a written deliverable and itemized hours.
When should a startup or university hire one?
NIH guidance suggests engaging help early in research for feasibility, and ideally after preclinical studies or initial design for pathway assessment. If an investor or licensee is asking about your regulatory path, you are already due for the conversation.
Do I need a consultant or an attorney?
Use a consultant for technical and compliance work like pathway selection and submission preparation. Use a regulatory attorney for enforcement defense, import detention or potential criminal exposure. For patents and licensing, you need an IP attorney, a separate specialty.
Sources
- Regulatory & Manufacturing Consulting for Life Sciences (NIH SEED)
- The Pre-Product Startup and the FDA (Y Combinator)
- Regulatory Consultation and Assistance Program (OHSU)
- SOPP 8101.1: Regulatory Meetings with Sponsors (FDA)
- Medical Device Premarket Approval and Postmarket Inspections, Part III (FDA)
- Certain Postapproval Requirements and Resources for ANDAs (FDA)
- FY 2016 Performance Report (FDA Office of Combination Products)
- FY 2019 OCP Performance Report (FDA)